Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,343 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) SVP Richard William Scalzo sold 1,343 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $15,283.34. Following the completion of the sale, the senior vice president now directly owns 122,330 shares of the company’s stock, valued at approximately $1,392,115.40. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $11.88 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The company has a 50 day moving average price of $15.10 and a 200 day moving average price of $25.73. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.34 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DYN. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $50.00 price target on the stock. Scotiabank started coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Finally, HC Wainwright dropped their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $48.85.

Get Our Latest Stock Report on DYN

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the 3rd quarter worth approximately $36,000. US Bancorp DE increased its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. Finally, KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Recommended Stories

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.